SCHEMBL4278875

SCHEMBL4278875

CN(CCCN1CCC(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1)C(=O)OC(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 11/20 0.60
RAD52 P43351 3/20 0.56
TP53 P04637 5/20 0.56
MAPK1 P28482 5/20 0.56
CYP1A2 P05177 4/20 0.56
HTR1A P08908 4/20 0.56
CYP2D6 P10635 4/20 0.56
CHRM1 P11229 4/20 0.56
SLC6A2 P23975 4/20 0.56
SLC6A4 P31645 4/20 0.56
ADRA1A P35348 4/20 0.56
DRD3 P35462 4/20 0.56
SLC6A3 Q01959 4/20 0.56
KCNH2 Q12809 4/20 0.56
ABCB1 P08183 3/20 0.56
ADRA2A P08913 3/20 0.56
ADORA3 P0DMS8 3/20 0.56
DRD1 P21728 3/20 0.56
THPO P40225 3/20 0.56
MTOR P42345 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3399336 0.90 FPR2 (0.65) FPR2RAD52TP53MAPK1CYP1A2
SCHEMBL4277176 0.90 FPR2 (0.57) FPR2RAD52TP53MAPK1CYP1A2
SCHEMBL4281962 0.88 FPR2 (0.55) FPR2RAD52TP53MAPK1CYP1A2
SCHEMBL4283601 0.86 TP53 (0.76) FPR2RAD52TP53MAPK1CYP1A2
SCHEMBL4274255 0.85 FPR2 (0.61) FPR2RAD52TP53MAPK1CYP1A2
SCHEMBL560706 0.84 FPR2 (0.58) FPR2RAD52TP53MAPK1CYP1A2
SCHEMBL30057046 0.82 FPR2 (0.68) FPR2RAD52TP53MAPK1CYP1A2
SCHEMBL26000676 0.82 FPR2 (0.68) FPR2RAD52TP53MAPK1CYP1A2
SCHEMBL4273505 0.82 FPR2 (0.75) FPR2RAD52TP53MAPK1CYP1A2
SCHEMBL13346862 0.81 LMNA (0.79) FPR2RAD52TP53MAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275557-A1 Novel Composition for Treatment of Diseases Related to Activated Lymphocytes IMMUNE CONTROL, INC. (US) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275557-A1 Novel Composition for Treatment of Diseases Related to Activated Lymphocytes TPH1, HTR5A, HTR6 FPR2 43/4885RAD52 3118/4885TP53 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.